Viewing Study NCT00123942



Ignite Creation Date: 2024-05-05 @ 11:46 AM
Last Modification Date: 2024-10-26 @ 9:12 AM
Study NCT ID: NCT00123942
Status: TERMINATED
Last Update Posted: 2007-06-14
First Post: 2005-07-22

Brief Title: Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
Sponsor: MedImmune LLC
Organization: MedImmune LLC

Study Overview

Official Title: Phase I Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
Status: TERMINATED
Status Verified Date: 2007-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of this study is to determine the maximum tolerated dose MTD and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None